Impact Therapeutics, a biotech company specializing in precision cancer drugs, saw its shares double on the first day of trading in Hong Kong after an IPO that was oversubscribed over 2000 times. The company’s lead product, senaparib, is a PARP inhibitor approved in China for advanced ovarian cancer and covered by public health insurance, which has helped it reach over 900 medical institutions. Despite heavy losses due to R&D spending, the IPO raised about $108 million to fund further drug development and commercialization. Investors are optimistic about the growing market for synthetic lethality drugs, though competition remains strong from established players like AstraZeneca and Hengrui Pharma.
The oligonucleotide drug development pipeline is rapidly expanding, featuring over 600 candidates from more than 200 companies including Novartis, Amgen, and Alnylam. These therapies target genetic diseases, cancers, and rare disorders using advanced...
The global cervical cancer diagnostics market is projected to grow at a compound annual growth rate (CAGR) of about 5% from 2026 to 2034, expanding from $4.4 billion in 2025 to $7.1 billion by 2034. This growth is fueled by rising cervical cancer pre...
AT&T, Verizon, and T-Mobile have agreed to collaborate by pooling spectrum resources and investing jointly in satellite-enabled direct-to-device technology to reduce wireless dead zones, especially in rural and underserved areas. This partnership aim...
Keycard announced Keycard for Multi-Agent Apps, a platform enabling secure, delegated, session-based access for autonomous AI agents. This system allows each AI agent to have its own verifiable identity and limits access strictly to the task at hand,...
Hut 8 and Fluence Energy secured major contracts in May 2026, confirming the critical role of land-based power and energy storage in the $725 billion AI infrastructure buildout. Hut 8 signed a $9.8 billion 15-year lease for a data center campus in Te...
